Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
复制标题
DOI：
10.1111/jdi.13122
复制
发表时间：
2019-08
影响因子：
3.2
通讯作者：
M. Tochiya;H. Makino;T. Tamanaha;Miki Matsuo;A. Hishida;R. Koezuka;Y. Ohata;Tsutomu Tomita;C. Son;Y. Miyamoto;S. Yasuda;K. Hosoda
中科院分区：
文献类型：
--
作者：
M. Tochiya;H. Makino;T. Tamanaha;Miki Matsuo;A. Hishida;R. Koezuka;Y. Ohata;Tsutomu Tomita;C. Son;Y. Miyamoto;S. Yasuda;K. Hosoda
最近的研究表明，钠-葡萄糖协同转运蛋白2抑制剂可降低2型糖尿病患者心力衰竭的风险。然而，这些药物的确切作用机制还不清楚。在本研究中，我们评估了26例2型糖尿病合并心脏病患者接受托福格列净治疗6个月对心脏和血管内皮功能的影响。托福格列汀治疗显著降低了左心室舒张末期尺寸，并显著增加了血流介导的血管舒张。尽管给药后E/e ′无显著变化，但观察到的E/e ′比值降低与乙酰乙酸和3-羟基丁酸水平升高显著相关。提示钠-葡萄糖协同转运蛋白2抑制剂可改善2型糖尿病患者左室扩张和血管内皮功能。此外，这表明钠-葡萄糖协同转运蛋白2抑制剂诱导的酮体升高可能有助于对左心室舒张功能障碍的保护作用。
Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end‐diastolic dimensions and significantly increased flow‐mediated vasodilation. Although E/e′ did not significantly change after treatment, the decrease observed in the E/e′ ratio was significantly correlated with the increase in acetoacetic acid and 3‐hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.